According to the Kidney Disease Outcomes Quality Initiative (KDOQI), PTX is recommended in patients with chronic kidney disease (CKD) stages 3–5, parathyroid hormone levels (PTH) beyond 800 ng/mL and no response to medical therapy [5]. The gene discussed is PTH; the disease is chronic kidney disease.